Form 4: Health In Tech CFO Granted 1M Restricted Shares

Health In Tech's CFO, LinLin Qian, was granted 1,000,000 restricted Class A Common Stock shares tied to two proposed company transactions.

Summary

• LinLin Qian, who serves as the Chief Financial Officer, a Director, and a 10% Owner of Health In Tech, Inc. (HIT), acquired 1,000,000 restricted shares of Class A Common Stock on January 6, 2026.
• These shares were granted under the Health in Tech Equity Incentive Plan at a price of $0, indicating an equity award.
• The grant is explicitly connected to two proposed issuer transactions, with vesting contingent upon their completion.
• Half of the granted shares (500,000) will vest in equal monthly installments over a 12-month period, commencing upon the closing of the first proposed transaction.
• The remaining half of the shares (500,000) will vest in equal monthly installments over 12 months, starting upon the closing of the second proposed transaction.
• All vesting is subject to LinLin Qian's continued service with the company.
• A critical condition is that if either of the proposed transactions does not close within 24 months after the grant date of January 6, 2026, the unvested shares related to that specific transaction will be automatically forfeited without any consideration.
• Following this transaction, LinLin Qian's beneficial ownership of Class A Common Stock totals 9,128,555 shares, which includes 1,119,130 restricted shares and 8,009,425 unrestricted shares.
• This reported beneficial ownership excludes 2,700,000 shares of Class B Common Stock and 711,510 options to purchase Class A Common Stock also held by LinLin Qian.

Sentiment

Score: 6

Explanation: The grant of restricted shares to a key executive is generally positive as it aligns interests. However, the contingency on two undisclosed 'proposed issuer transactions' introduces a degree of uncertainty and risk regarding the ultimate vesting and successful completion of these strategic initiatives.

Positives

• The grant of 1,000,000 restricted shares to a key executive (CFO, Director, and 10% Owner) strongly aligns management's long-term interests with shareholder value, particularly as it is tied to the successful completion of strategic corporate transactions.
• The utilization of the equity incentive plan encourages long-term commitment and performance from a critical member of the management team.

Negatives

• The vesting of the restricted shares is contingent upon the completion of two 'proposed issuer transactions,' the details of which are not disclosed, introducing an element of uncertainty regarding their successful execution.
• The forfeiture clause, which stipulates that unvested shares will be lost if the transactions do not close within 24 months, highlights a potential risk associated with these undisclosed strategic initiatives.

Risks

• Risk of forfeiture of unvested shares if the two proposed issuer transactions do not close within 24 months after January 6, 2026.
• Uncertainty surrounding the nature, terms, and successful completion of the 'two proposed issuer transactions' mentioned as conditions for vesting.

Future Outlook

The vesting schedule for the restricted shares is directly tied to the closing of two proposed issuer transactions, indicating that the company anticipates completing these strategic initiatives within the next 24 months from January 6, 2026.

Management Comments

• "Represents restricted shares of Class A Common Stock granted pursuant to the Health in Tech Equity Incentive Plan in connection with two proposed issuer transactions."
• "Half of the shares vest in equal monthly installments over 12 months starting at the closing of the first Transaction."
• "The other half vest in equal monthly installments over 12 months starting at the closing of the second Transaction."
• "Vesting is subject to continued service."
• "If either Transaction does not close within 24 months after January 6, 2026 (the 'Grant Date'), unvested shares relating to that Transaction will be automatically forfeited without consideration."

Industry Context

na

Corporate Governance

Stakeholder Impact

• Shareholders: Potential positive impact if the proposed transactions are successful, leading to increased shareholder value. There is a risk of future dilution if the shares vest, but this is balanced by the alignment of management incentives.
• Employees: The use of an equity incentive plan for a key executive could signal a broader strategy for employee retention and motivation, although this specific grant is for a senior leader.

Next Steps

• Completion of the first proposed issuer transaction, which will trigger the commencement of vesting for 500,000 restricted shares.
• Completion of the second proposed issuer transaction, which will trigger the commencement of vesting for the remaining 500,000 restricted shares.
• Continued service by LinLin Qian to ensure the vesting of the restricted shares.

Key Dates

Recommendation

The grant of 1,000,000 restricted shares to the CFO, a significant insider, is a positive signal of management's commitment and alignment with future company performance, particularly tied to two proposed strategic transactions. However, the details of these transactions are undisclosed, and the vesting is contingent upon their successful completion within 24 months, introducing an element of uncertainty. Without further information on the nature and potential impact of these transactions, a 'hold' recommendation is prudent, awaiting more clarity on the company's strategic direction and execution.

Keywords

Health In Tech, HIT, Form 4, Beneficial Ownership, Restricted Stock, Equity Incentive Plan, CFO, Director, Executive Compensation, Stock Grant, Vesting, Corporate Transactions